Tessari Eben, chief strategy officer at Kiniksa Pharmaceuticals (KNSA), has filed 55 Form 4 transactions with the SEC, all tied to a single company. The pattern is unambiguous: zero open-market purchases and roughly $13.4 million in total sales, with the most recent activity concentrated in late 2025 and early 2026. Eben’s selling has been steady and substantial, including a $1.6 million sale on September 29, 2025, a $584,804 disposition on September 15, and a $500,715 sale on December 15. Smaller open-market sales of $8,578 and $25,852 occurred in November, alongside a $488,373 block on November 17. The largest single transaction was the September 29 sale, which coincided with an option exercise valued at $752,640, suggesting the shares sold were acquired through equity compensation rather than bought on the open market.
The recent filings from April 2026 show no sales at all. Instead, they reflect routine administrative activity: option exercises valued at $0, restricted stock awards, and two tax-withholding events (code F) totaling $125,919. These are automatic deductions to cover tax liabilities, not discretionary trades. The last actual open-market sale occurred on December 15, 2025, and since then Eben has only engaged in compensation-related transactions. Over the full filing history, Eben has acquired $20,572 in shares through grants or exercises, a figure dwarfed by the $13.4 million in total sales. The data paints a clear picture of an insider who has consistently monetized equity awards over the past year, with no corresponding purchases to signal conviction in the stock’s upside.
AI-assisted summary